Ventrix Bio Extracellular Matrix

Phase 1Small molecule

Ventrix Bio Extracellular Matrix is one of 3 small molecule programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypoplastic Left Heart SyndromeNot yet recruiting

Hypoplastic Left Heart SyndromePhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Hypoplastic Left Heart Syndrome

#DrugCompanyPhaseTrials

Letairis

Tepadina

Ventrix Bio Extracellular Matrix

EEmory University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Hypoplastic Left Heart Syndrome

NCT06461676

Clinical

Trials by Indication[1]

Hypoplastic Left Heart Syndrome1 trial

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

Not yet recruiting·EEmory University·Phase 1·NCT06461676·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ventrix Bio Extracellular Matrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ventrix Bio Extracellular Matrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ventrix Bio Extracellular Matrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emory University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEmory University

Ventrix Bio Extracellular Matrix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Hypoplastic Left Heart Syndrome1 trial

References

Drug Info

Quick Facts

Related News